Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PCI Biotech Holding ASA ( (DE:4QG) ) has issued an announcement.
PCI Biotech Holding ASA announced that shareholders at an extraordinary general meeting on 16 March 2026 approved all agenda items, including a resolution to liquidate the company and seek delisting of its shares from Euronext Oslo Børs. The liquidation is expected to be completed in the first half of 2026, marking an effective wind-down of the company’s operations and public listing, with significant implications for investors as the firm exits the public market.
The decisions taken at the meeting formalize the transition of PCI Biotech into liquidation status and initiate the process for removing its shares from trading on the Oslo exchange. This development signals the end of PCI Biotech’s presence as a listed biotech entity in Norway, and sets the framework for how remaining assets and obligations will be handled for shareholders and other stakeholders.
More about PCI Biotech Holding ASA
PCI Biotech Holding ASA is a Norwegian biotechnology company that has been listed on Euronext Oslo Børs. The company has focused on developing medical technologies and treatments, positioning itself within the life sciences sector and targeting specialized healthcare markets.
YTD Price Performance: -14.63%
Average Trading Volume: 958,637
Current Market Cap: NOK7.84M
For an in-depth examination of 4QG stock, go to TipRanks’ Overview page.